PriceSmart Inc and Yum China shares fall after earnings disappoint - AFTER HOURS
We care covering the after hours buzz stocks in New York
Company
Merck & Co Inc
NYSE:MRK
Merck & Co Inc is a global healthcare company. The company offers health solutions through its prescription medicines, including biological therapies, vaccines and animal health products.
138 stories · page 6 of 7
Merck and Gilead among drug stocks buoyed by Trump’s healthcare plans
The Republicans are looking to repeal Obamacare as well as trying to ease regulatory pressures in the industry
Merck shares slide as drugs giant forced to halt enrolment of two late-stage cancer studies
The two studies – KEYNOTE-183 and KEYNOTE-185 – were testing Keytruda in combination with other therapies to treat multiple myeloma
Strategic Elements progressing printable memory ink technology
Outcomes of recent work in Finland will be reviewed in the next few weeks.
AstraZeneca, Merck and Bristol-Myers vying for dominance in lung cancer market
Merck seems to be ahead in the race to develop the number one lung cancer treatment, but for how long?
Merck gets Keytruda go-ahead as a first line lung cancer treatment
Lung cancer in the US alone is a market worth at least US$12bn a year.
Merck & Co raises forecasts again as new drugs prove worth
Prescription drugs overall chipped in sales of US$8.2bn out of a total US$9.43bn
PDL Biopharma rises in pre-market as Merck shells out US$19.5mln to settle patent suit
The settlement relates to Merck’s Keytruda skin cancer treatment
Merck receives diabetes drug labelling setback
Merck received a Complete Response Letter from the US Food and Drug Administration on the use of Sitagliptin
Cancer drug Keytruda lifts Merck
Keytruda has been approved in the US and elsewhere for new lung cancer patients
US shares end mixed in heavy earnings day
US shares closed mixed on Thursday after an earnings-heavy session and a deceleration in New York manufacturing activity
AbbVie's revenue miss clouds strong Humira US sales
AbbVie Inc shares were lower on Friday after the pharma reported quarterly adjusted revenue that missed analysts' estimates as weaker-than-expected sales of its hepatitis C treatment and cancer therapy overshadowed strong US demand for its
US stocks trend higher, but unfazed by Trump’s damp inauguration
US stocks closed higher on Friday, but little changed following Donald Trump’s first speech as President
US FDA agrees to accelerated review of Merck immunotherapy drug combination treatment for lung cancer
Merck said the FDA would decide by May 10 whether to OK the Keytruda combination treatment, with the drug already approved for first-line treatment of lung cancer patients.
US shares end up as oil investors crowd out depressed pharma post-Trump speech
US shares ended higher on Wednesday, as energy investors shrugged off a jump in US oil stocks, and markets took a sanguine view of President-elect Donald Trump’s first speech since he won the November election
Merck's Keytruda close to Europe approval as chemotherapy alternative
Keytruda has already been cleared in Europe for second line use
Gilead order to pay US$2.54bn in royalties after losing patent battle
It is the biggest patent-infringement verdict in US history and, of course, the loser is appealing against it.
Trending: Which 80 small- mid- and large-cap stocks will do well over four years?
Watching the way Wall Street index tickers have raced to fresh record highs on both Monday and Tuesday, investors might be forgiven for thinking that pretty much any stock is doing well on the so-called “Trump Trade”, coined in the wake of
US small-caps among the top risers after Trump victory
US stocks snapped back from initial losses to close Wednesday higher and the Dow even managed an intraday record peak, while small-caps had one of their best days in 14 years, after Donald Trump and the Republicans’ sweep into office
Bristol Myers suffers again after more Keytruda success
In combination with established chemotherapy drugs Keytruda was twice as effective as chemotherapy alone.